experimental drug [Drug condition], while the remaining half of participants were placed in a placebo condition in which they received a sham pharmacological treatment (Placebo condition]. They measured a continuous-valued, composite index of allergic reaction symptomology to examine whether those who received the experimental drug treatment showed a reduction in allergic reaction symptomology [see Table 5 below). Upon preliminary analysis, the researchers discovered that the assumption of homogeneity of variance was violated: 2 Slargest 6- 79 Fmax = 52 : m = 4.07, Fmaxcrit = 4.04 . smallest Furthermore, they realized that the dependent variable was not normally distributed, as scores were heavily positively skewed. Given these observations, using a parametric analysis of the mean difference between conditions is not appropriate. What can the researchers conclude about the efficacy of the drug using a non-parametric analysis? Show all relevant descriptive statistics. Table 5. Composite allergic reaction symptomology scores in the Drug and Control conditions. Subject Condition Scores 1 Drug 1.05 2 Drug 0.70 3 Drug 2.10 4 Drug 0.20 5 Drug 1.91 6 Drug 1.38 7 Drug 1.09 8 Drug 4.41 9 Drug 0.29 10 Drug 0.02 11 Placebo 5.73 12 Placebo 8.21 13 Placebo 6.70 14 Placebo 1.00 15 Placebo 2.02 16 Placebo 3.33 17 Placebo 6.19 18 Placebo 8.47 19 Placebo 2.67 20 Placebo 5.92